AbbVie's SKYRIZI Wins EC Approval for Pediatric Psoriasis, Expanding European Market
ABBV sits 27% above its 52-week low of $181.73.
Summary
The European Commission has approved AbbVie's SKYRIZI (risankizumab) for treating moderate to severe plaque psoriasis in pediatric patients aged six and older. This regulatory win expands the market for SKYRIZI, a key immunology drug, into a new patient population in Europe. The approval includes a new weight-based dosing option. This positive development for SKYRIZI follows AbbVie's recent $10.9 billion acquisition of Apogee Therapeutics, further strengthening its immunology portfolio.
At the time of this announcement, ABBV was trading at $229.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $406.4B. The 52-week trading range was $181.73 to $244.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.